Del Mar

Researchers are evaluating the effects of a health and wellness product on gastrointestinal health and related outcomes in adults aged 21 to 75. This study aims to understand user experiences, side effects, product acceptance, and health impacts in people currently using GLP-1 medications for at least 3 months or those interested in losing weight but not on GLP-1 therapy. The study is sponsored by PepsiCo Global R&D and uses self-reported measures and biomarker collections to assess outcomes. Participants will consume a ready-to-mix beverage containing protein, fiber, and electrolytes freely over a 4-week period. The study includes adults who either have been taking GLP-1 for 3 months or longer without plans to stop or switch, or those interested in weight loss but not currently using GLP-1 and with no plans to start. Biomarker collections of stool and blood samples will occur at the start and end of the intervention period. During the study, participants will complete electronic surveys measuring constipation, belly pain, digestion quality of life, satiety, and self-reported weight at baseline and weekly during the 4 weeks. They will also keep a 24-hour food diary at the beginning and end of the study. Researchers will monitor participant health and product effects through these assessments and biomarker samples. The study is open label with no blinding, and participants must have reliable internet access to complete electronic surveys and biomarker collections. Total participation lasts for the 4-week intervention.

Researchers are evaluating whether using the HAPPI software can improve how pharmacists provide birth control services and how easily patients can access these services. This trial focuses on comparing pharmacist implementation and patient access with and without the HAPPI software to see if it offers improvements. The study involves 15 community pharmacies that will first continue their usual birth control services for several months without the software. Then, the HAPPI software will be introduced to replace previous paper or electronic processes as pharmacists continue providing birth control services. Outcomes during the control and intervention periods will be compared. Participants include pharmacists who provide birth control services and patients who receive these services at participating pharmacies. Researchers will measure aspects such as the number of pharmacists and pharmacy staff involved, payment methods like cash or insurance billing, and overall access to care during the study period of up to 5 months. The study is sponsored by EMPOWERX INC and runs through August 2026.

This trial evaluates the use of the PEPPI software to improve pharmacist-provided HIV prevention services, specifically post-exposure prophylaxis PEP and pre-exposure prophylaxis PrEP. It aims to find out if the software can make it easier for pharmacists to deliver these services and for patients to access them. The study compares service delivery and patient access with and without the software in community pharmacies. The study involves 10 community pharmacies that first provide PEPPrEP services as usual control period. Then, the pharmacies introduce the PEPPI software in two phases the initial minimally viable product MVP version followed by an enhanced version. Pharmacists use the software to replace previous paper or electronic processes for providing PEPPrEP services during the intervention periods. Participants include pharmacists who provide PEPPrEP services using the software and patients who receive these services at participating pharmacies. Researchers measure outcomes related to service implementation such as number of pharmacists and staff involved, payment methods like cash or insurance billing, and implementation outcomes up to 12 months. They also assess patient access to care during this time. The study runs from August 2026 to September 2028.

Researchers are evaluating the effects of health and wellness products on cognitive function and related health outcomes in adult E-Gamers and young professionals aged 21 to 45. This randomized, double-blind, placebo-controlled study aims to investigate potential improvements in cognition and fatigue among participants residing in the United States. The study includes individuals who may experience at least a 30% improvement in their primary health outcome and are willing to take a product without knowing its formulation during the study. Participants will be randomly assigned to one of two groups one receiving a Clarity Active Product and the other receiving a placebo version of the Clarity product. Both are dietary supplements used as directed over an 8-week period. The study is conducted entirely remotely, with no in-person visits required. Data collection occurs electronically throughout the 9-week study period, including enrollment and active product use. Participants will provide self-reported health data electronically, including measures of cognitive function, cognitive abilities, and fatigue, collected at enrollment and regularly during the study. The primary outcome is change in cognitive function over 9 weeks, with additional measures on cognitive abilities and fatigue. There are no onsite visits, and all assessments are done through electronic means to track health indicators and adherence to the study products.

Researchers are evaluating the impact of health and wellness products on mental clarity and related health outcomes in adults aged 35 to 60 years living in the United States. This randomized, double-blind, placebo-controlled study aims to observe meaningful improvements in cognitive function and other related measures over 12 weeks. Participants agree to use a study product without knowing its exact formulation during the trial to ensure unbiased results. Participants are randomly assigned to use either the RS Clarity Active Product or a placebo version of the Clarity Product for 12 weeks. Both products are dietary supplements taken as directed. This direct-to-consumer study collects all data electronically, with no in-person visits required, allowing participants to complete assessments remotely. Throughout the 12-week period, participants will regularly report health indicators related to cognitive function, fatigue, sleep-related impairment, and cognitive abilities using electronic methods. Researchers will measure changes in cognitive function at 13 weeks as the primary outcome. Safety is monitored by excluding individuals with certain medical conditions or medication interactions. Participants provide self-reported data without in-person assessments, making the study convenient and accessible.

This research aims to evaluate the effects of health and wellness products on menopausal-related health issues, focusing on cognitive function and hot flash symptoms. The study is a randomized, double-blind, placebo-controlled trial involving adult women who are peri or postmenopausal and regularly experience hot flashes. It targets those not currently using hormone replacement therapy and excludes individuals with significant health risks or contraindications. Participants will be randomly assigned to use either an active Revive health product or a placebo control product for 12 weeks. Both groups will follow product use as directed, with no knowledge of their assigned product until the studys conclusion. The trial is conducted entirely remotely, without in-person visits, and collects data electronically. During the 13-week study period, participants will self-report health outcomes such as cognitive function, feelings of anxiety, hot flash frequency, intensity, and interference through electronic surveys. The study monitors these measures throughout the product use period, with the primary outcome being change in cognitive function. Participants are expected to have internet access to provide daily data. Safety and adherence are observed through remote data collection and electronic reporting.